Cumberland Pharmaceuticals focuses on developing and commercializing prescription products for hospital acute care, gastroenterology, and oncology. Its products include injections for treating acetaminophen poisoning, pain and fever, and certain infections. The company also develops treatments for constipation, Helicobacter pylori infection, duodenal ulcer disease, and hyponatremia. Additionally, Cumberland Pharmaceuticals is developing a treatment for rheumatoid arthritis and psoriasis, as well as a product candidate for aspirin-exacerbated respiratory disease and other conditions. The company has completed phase II clinical trials for certain products and is headquartered in Nashville, Tennessee.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |